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Introduction
Japanese Encephalitis (JE) is a disease primarily dominant in South East Asia, caused
by the Japanese Encephalitis virus (JEV, a Flavivirus, Figure 1). It is responsible for an
estimated 50,000 cases of the disease every year, of which around 10,000 are fatal and
approximately 15,000 result in long term neurological sequelae (WHO 2006).
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Experimental Design




pH 7 8 9
Temperature (°C) 22 28.5 35
Glycerol (%) 0.1 0.55 1
Sorbitol (%) 0.1 0.55 1
Lysine (%) 0.05 0.275 0.5
Glycine (%) 0.05 0.275 0.5
PEG (%) 0.1 0.55 1
Table 1 – Inactivation factors investigated with the high (+1), low (-1) and mid-point (0)
ranges of the design for temperature, pH and final concentrations of the components
added. The 32 sets of conditions will be a combination of -1 and +1 of each factor.
Conclusions & optimisation potential
• Using an increase in pH to mitigate against antigen loss at higher formaldehyde
concentrations has implications for inactivation times as more rapid inactivation of
JEV particles can be achieved (Darwish et al. 1966). Furthermore, temperature can
also be used to decrease inactivation times as it is shown to have little effect on
antigen integrity.
Viral inactivation is a principle feature in many vaccine
manufacturing processes in order not only to
inactivate the product itself but also any potential
adventitious agents which may have been introduced
during manufacture. Inactivation using formaldehyde
is one of the most common methods used for
inactivated viral vaccines, yet due to the relatively
unpredictable nature of the protein cross linking
method by which inactivation occurs, antigen recovery
rates can vary significantly (Fraenkel-Conrat &
Mecham 1949, Metz et al. 2003).
This poster seeks to use a design of experiments
based methodology to investigate viral inactivation
step of JEV. The current manufacturing conditions are
non-optimal in terms of inactivation time and antigen
recovery. Several key variables of the formaldehyde
inactivation of JEV have been identified from the
literature for investigation: temperature, pH,
formaldehyde concentration and the presence of
stabilisers (glycerol, sorbitol, lysine, glycine and PEG).
As a factor screening experiment, a two level factorial design will be presented
involving 36 experimental runs including 4 centre points. The measured effect will be
antigen recovery measured by ELISA specific to the vaccine. The data will determine
which of the factors are the most significant and which factors contribute to
interaction effects with regards to optimal inactivation of JEV for use in a vaccine.
Figure 1 – Image 
representing the structure 
of a typical Flavivirus.
• 2-level factorial design 
with 8 factors, as described 
in table 1, created using 
Design Expert.
• 36 experimental runs 
conducted, including 4 mid-
points and 32 different sets 
of  inactivation conditions, 
run for  96 hours.
• Antigen recovery based on 
ELISA was the measured 
response.
• Experiments performed in 
deep well plates with a 
working volume of 3 mL of 
purified JEV. 
Results
• Formaldehyde concentration was found to have the most significant impact on
antigen recovery, followed, in order of relative significance, by the interaction of pH
and formaldehyde concentration, glycine concentration, pH and sorbitol concentration,
as illustrated in Figure 2.
• Using higher formaldehyde concentrations alone would harm the vaccine quality,
requiring more virus total virus per dose. It is also suggested that glycine, and to a
lesser extent sorbitol, could potentially increase vaccine quality.
Design-Expert® Software
Log10(Antigen recovery)















































Figure 2 – Plot illustrating 
relative significance of 
each factor investigated. 
The further a factor is away 
from the line, the more 
significant the factor.
• It is possible that these stabilisers protect the antigen somewhat from the damaging
effects of formaldehyde. It has previously been stated that glycine bonds with peptide
sites which may normally form inter- and intra- molecular bonds in the presence of
formaldehyde (Metz et al. 2003).
• The software used the results to generate a model for the inactivation of JEV within
the range of variables investigated. This was used to produce a 3-D surface
representing the interaction between pH and formaldehyde concentration. As can be
seen in Figure 3, in order to mitigate the negative effects of higher formaldehyde
concentrations on antigen recovery rates the inactivation should be performed at a
higher pH. This figure also illustrates the effect of using the two most significant
stabilisers investigated, glycine and sorbitol, at higher concentrations, predicting






X1 = A: Formaldehyde concentration
X2 = B: pH
Actual Factors
C: Temperature = 28.50
D: Glycine = 0.50
E: Lysine = 0.28
F: Sorbitol = 1.00
G: Glycerol = 0.55








































  A: Formaldehyde concentration  
  B: pH  
Figure 3 – Modelled 3-
D plot of the 
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• The model is considered statistically significant, as F = 45.972, p < 0.0001, and
therefore useful for prediction, as illustrated by Figure 4, which plots predicted versus
actual results using the equation:
Where y = antigen recovery, A = formaldehyde concentration, B = pH, D = glycine
concentration and F = sorbitol concentration.
Figure 4 – Plot of predicted 
versus actual data. The 
closer the points to the line, 
the better the model is at 
predicting results.
ABFDBAyLog 41.2716.002.165.043.25017.6)(10
Potential improvement over starting conditons
0.00 2.00 4.00 6.00 8.00 10.00 12.00
% increase in antigen recovery
0.02% formaldehyde, pH 7, 0.5% glycine, 1% sorbitol
0.04% formaldehyde, pH 9, 0.5% 
glycine, 1% sorbitol
0.02% formaldehyde, pH 7, 0.5% 
glycine, 1% sorbitol
0.02% formaldehyde, pH 7.5, 0.5% glycine, 1% sorbitol
• Figure 5 illustrates the potential
improvement over the starting
conditions certain modifications may
have, including the use of stabilisers,
which could have uses elsewhere in a
process.
•The potential for optimisation would
include investigations into the effect
on other responses, such as product
aggregation, inactivation kinetics and
stability. This, in conjunction with
increasing the observed ranges of
significant factors, would allow for
the identification of optimal ’windows
of operation’ for the given set of
factors.
Figure 5 – potential increase in antigen recovery
over starting conditions.
